AKL International HomeAKL International - Who we are and Our VisionAKL International - PortfolioAKL International - Latest NewsAKL International - Contact Information
AKL International Ltd is involved in research, discovery and commercial development of clinically effective drugs from botanical sources.
 
Ongoing research programs cover asthma, COPD (targeting chronic bronchitis and emphysema), cystic fibrosis and diseases of the joints, muscles and bones (specifically targeting osteoarthritis).
 
Working with leading research groups, AKL undertakings include the most common comorbidities associated with COPD: high blood pressure, diabetes, coronary artery disease, cholesterol, heart failure, cancer and pulmonary vascular disease.